Medicare Risk Arrangement and Use and Outcomes Among Physician Groups
At-risk Medicare Advantage arrangements show higher quality and efficiency compared to fee-for-service models, impacting care delivery for beneficiaries.
- Publisher
- APG
- Published
- Length
- 82 pages
- File
- 4.2 MB PDF
Quick answer
Medicare Risk Arrangement and Use and Outcomes Among Physician Groups is a 82-page whitepaper from APG covering US pharma intelligence. At-risk Medicare Advantage arrangements show higher quality and efficiency compared to fee-for-service models, impacting care delivery for beneficiaries.
Why this matters
At-risk Medicare Advantage arrangements show higher quality and efficiency compared to fee-for-service models, impacting care delivery for beneficiaries.
Executive summary
- At-risk Medicare Advantage arrangements show higher quality and efficiency compared to fee-for-service models, impacting care delivery for beneficiaries.
Market Impact
| Regulatory | high |
|---|---|
| Commercial | high |
| Competitive | medium |
| Investment | high |
Who should read this
- Regulatory affairs teams
Ask about this report
AI-assisted answers grounded in NovaPharmaNews intelligence
Answers use retrieved site intelligence plus AI synthesis. Verify critical decisions with primary sources.
Download the full 82-page PDF
Free · 4.2 MB · Instant access after email
This cross-sectional study analyzes the quality and efficiency of care under at-risk Medicare Advantage (MA) arrangements versus fee-for-service (FFS) models.
- Data from 2016-2019 covering 5,278,717 person-years were examined.
- At-risk MA arrangements resulted in lower inpatient admissions and emergency department visits.
- Quality measures favored at-risk MA in 18 of 20 evaluated metrics.
- Findings suggest improved healthcare delivery for Medicare beneficiaries under at-risk payment models.
- Study highlights the importance of payment arrangements in influencing care quality.
Frequently asked questions
What whitepapers does NovaPharmaNews publish?
Our research library curates FDA, EMA, and industry publisher PDFs — regulatory guidance, clinical analyses, manufacturing reports, and market intelligence. Each report includes an AI-summarized landing page with key takeaways and a gated PDF download.
How do I download a whitepaper?
Open any report page, scroll to the download form, and enter your work email. You receive instant PDF access and can opt in to weekly pharma intelligence updates. Downloads are free for healthcare professionals.
How do whitepapers connect to news and pipeline data?
Report pages link to related intelligence — company profiles, drug INN pages, clinical trials, pipeline programs, and topic hubs. Use the intelligence spokes on each page to explore the entity graph behind the research.
Ready to read the full report?
Join 12,000+ pharma leaders getting deep industry analysis delivered weekly.
Related topic hubs
Editorial coverage and intelligence directories for this report's beat.
Explore the intelligence platform
Related intelligence
🔒 IFPMA IDAP whitepaper: end-to-end access pathway for innovative medicines and vaccines
IDAP is a holistic framework spanning four linked phases: Research and Development; regulatory processes and product registration; listing, …
🔒 IFPMA whitepaper: How assessment reports enable regulatory reliance in pharma
Regulatory reliance helps NRAs avoid duplicative reviews and allocate resources more efficiently by leveraging prior scientific evaluations …
🔒 Integrated delivery networks in Middle East healthcare: what PwC says about the next phase of care
Scale creates value only when healthcare assets are connected through shared systems, referral flows and coordinated management disciplines